RE: [ozmidwifery] Misoprostol & the Third stage of Labour

[LJG]

Hi Abby
Completely agree...ALL drugs used during labour and birth can have nasty
effects especially when misused...I am by no means promoting it, these posts
were of interest in terms of appropriate use...some would say that the
warnings placed on this drug by its makers are because they have no further
need to spend money researching and marketing it's use in obstetrics,
because it is so widely used...if they supported this use, they would need
to spend money supporting their recommendations!
I'm not sure if it is used anywhere in Oz for induction?this is where
most of the concerns with uterine rupture occur especially with a uterine
scar.
Lisa

 

-Original Message-
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] On Behalf Of
[EMAIL PROTECTED]
Sent: Friday, 17 November 2006 7:48 PM
To: ozmidwifery@acegraphics.com.au
Subject: Re: [ozmidwifery] Misoprostol & the Third stage of Labour


There seems to be a lot of posts about Misoprostol but no talk of the
increased risk this drug puts women at for uterine rupture. It can be quite
a nasty drug and the pharmaceutical company that manufacture misoprostol aka
cytotec have issued warnings against using the drug for women during
childbirth.

Love Abby



> 


--
This mailing list is sponsored by ACE Graphics.
Visit <http://www.acegraphics.com.au> to subscribe or unsubscribe.

RE: [ozmidwifery] Misoprostol & the Third stage of Labour

[LJG]

Mary there are some systematic reviews which include these studies but am
unable to get a hold of the full text..will try at work. L

-Original Message-
From: [EMAIL PROTECTED]
[mailto:[EMAIL PROTECTED] On Behalf Of Mary Murphy
Sent: Friday, 17 November 2006 6:51 PM
To: ozmidwifery@acegraphics.com.au
Subject: RE: [ozmidwifery] Misoprostol & the Third stage of Labour


It always amazes me that these trials are on such a small number of women.
While they are interesting, surely they are not able to be applied to the
wider population of women? MM 

"Results for the intravenous oxytocin (n = 311) and oral misoprostol (n =
311) groups are as follows" 
--
This mailing list is sponsored by ACE Graphics.
Visit <http://www.acegraphics.com.au> to subscribe or unsubscribe.


--
This mailing list is sponsored by ACE Graphics.
Visit <http://www.acegraphics.com.au> to subscribe or unsubscribe.

RE: [ozmidwifery] Misoprostol & the Third stage of Labour

[Mary Murphy]

It always amazes me that these trials are on such a small number of women.
While they are interesting, surely they are not able to be applied to the
wider population of women? MM 

"Results for the intravenous oxytocin (n = 311) and oral misoprostol (n =
311) groups are as follows" 
--
This mailing list is sponsored by ACE Graphics.
Visit  to subscribe or unsubscribe.

Re: [ozmidwifery] Misoprostol & the Third stage of Labour

[abby_toby]

There seems to be a lot of posts about Misoprostol but no talk of the increased 
risk this drug puts women at for uterine rupture. It can be quite a nasty drug 
and the pharmaceutical company that manufacture misoprostol aka cytotec have 
issued warnings against using the drug for women during childbirth.

Love Abby



> LJG <[EMAIL PROTECTED]> wrote:
> 
> 
> 
> Ovid Technologies, Inc. Email Service
> --
> Results: Obstetrics & Gynecology 
> 
> (C) 2005 The American College of Obstetricians and Gynecologists
> 
> Volume 105(4) Supplement, April 2005, p 39S
> 
> Prophylactic Use of Misoprostol in the Third Stage of Labor [Papers on
> Current Clinical and Basic Investigation: Poster Sessions: Monday, May 
> 9,
> 2005: Obstetrics]
> 
> Baskett, Thomas F. MB; Persad, Vidia MB; Clough, Heidi RN; Young, David 
> MD
> Dalhousie University, Halifax, Nova Scotia, Canada (Baskett)
> 
> --
> 
> Outline
> 
>   OBJECTIVE:
> 
>   METHODS:
> 
>   RESULTS:
> 
>   CONCLUSIONS:
> 
> OBJECTIVE:
> 
> To assess the effectiveness of oral misoprostol in comparison with
> intravenous oxytocin in reducing bleeding during the third stage of 
> labor.
> 
> METHODS:
> 
> A double-blind, randomized controlled trial comparing oral misoprostol 
> 400
> [mu]g and intravenous oxytocin 5 U, given after delivery of the anterior
> shoulder of the fetus, was performed. The primary outcome was a 
> hematocrit
> drop greater than 10% at 24 hours postpartum. Secondary outcomes 
> included
> hemoglobin drop greater than 30%, need for additional oxytocics, blood 
> loss
> greater than 1,000 mL, manual removal of placenta, blood transfusion, 
> and
> the adverse effects of shivering and fever.
> 
> RESULTS:
> 
> Results for the intravenous oxytocin (n = 311) and oral misoprostol (n =
> 311) groups are as follows (expressed as percentages of each group):
> hematocrit drop greater than 10%, 3.4% and 3.7%, respectively (P = NS);
> hemoglobin greater than 30%, 8.9% and 10.2%, respectively (P = NS); 
> blood
> loss greater than 1,000 mL, 2.3% and 4.5%, respectively (P = NS); manual
> removal of placenta, 8.0% and 8.0%, respectively (P = NS); additional
> oxytocics, 40.5% and 51.1%, respectively (P P P 
> 
> CONCLUSIONS:
> 
> Oral misoprostol is as effective as intravenous oxytocin in reducing 
> loss at
> delivery but is associated with an increased need for additional 
> oxytocic
> drugs. The adverse effects of shivering and fever were only present with
> misoprostol but were not clinically troublesome.Accession Number:
> 6250-200504001-00088
> 
> 
> --
> This mailing list is sponsored by ACE Graphics.
> Visit  to subscribe or unsubscribe.
--
This mailing list is sponsored by ACE Graphics.
Visit  to subscribe or unsubscribe.